FDA Approves ALYFTREK for Rare Pediatric Disease, Redeems Priority Review Voucher

Summary

The FDA has approved ALYFTREK, a treatment for a rare pediatric disease, and redeemed a priority review voucher, following a review of the application submitted by the manufacturer.